Matrizyme Pharma Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Financing Rounds
  • 3

Matrizyme Pharma General Information

Description

Developer of licensed and patented pharmaceutical drugs intended to facilitate angioplasty. The company operates as a privately-held biopharmaceutical firm that specializes in developing medicinal drugs, through the use of advanced therapeutics focusing on the area of interventional cardiology, by developing a drug that uses collagenase, enabling patients suffering from chronic total occlusions of coronary arteries to get easier stenting procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Corporate Office
  • 512-555 Richmond Street West
  • Toronto, Ontario M5V 3B1
  • Canada
+1 (905)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 512-555 Richmond Street West
  • Toronto, Ontario M5V 3B1
  • Canada
+1 (905)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Matrizyme Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Matrizyme Pharma‘s full profile, request access.

Request a free trial

Matrizyme Pharma Patents

Matrizyme Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2589523-A1 Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions Active 02-Dec-2004
CA-2589523-C Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions Inactive 02-Dec-2004
EP-1827484-A1 Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions Active 02-Dec-2004
EP-1827484-A4 Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions Active 02-Dec-2004
EP-1827484-B1 Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions Inactive 02-Dec-2004 A61K38/4886
To view Matrizyme Pharma’s complete patent history, request access »

Matrizyme Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Matrizyme Pharma‘s full profile, request access.

Request a free trial

Matrizyme Pharma FAQs

  • When was Matrizyme Pharma founded?

    Matrizyme Pharma was founded in 2003.

  • Where is Matrizyme Pharma headquartered?

    Matrizyme Pharma is headquartered in Toronto, Canada.

  • What industry is Matrizyme Pharma in?

    Matrizyme Pharma’s primary industry is Biotechnology.

  • Is Matrizyme Pharma a private or public company?

    Matrizyme Pharma is a Private company.

  • What is Matrizyme Pharma’s current revenue?

    The current revenue for Matrizyme Pharma is .

  • How much funding has Matrizyme Pharma raised over time?

    Matrizyme Pharma has raised $9.2M.

  • Who are Matrizyme Pharma’s investors?

    Ontario Bioscience Innovation Organization has invested in Matrizyme Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process